Skip to main content
Telix Pharmaceuticals Ltd logo

Telix Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · TLX ISIN · AU000000TLX2 ASX Manufacturing
Open in API
Filings indexed 989 across all filing types
Latest filing 2023-09-05 Share Issue/Capital Cha…
Country US United States of America
Listing ASX TLX

About Telix Pharmaceuticals Ltd

https://telixpharma.com/

Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, an approach known as 'theranostics'. The company utilizes targeted radiation to both image and treat various forms of cancer. Its extensive clinical pipeline and portfolio address key areas in oncology, including urologic (prostate and kidney), neurologic (glioma), and musculoskeletal cancers, as well as applications in bone marrow conditioning. Telix has secured global regulatory approvals for its prostate cancer imaging agent and supports its products with a robust global supply, manufacturing, and distribution network. The company is actively engaged in numerous clinical trials worldwide to expand its theranostic platform.

Recent filings

Filing Released Lang Actions
Application for quotation of securities - TLX 9 pages 36.3KB
Share Issue/Capital Change Classification · 100% confidence The document is an application for quotation of securities on the ASX by Telix Pharmaceuticals Limited. It details the issuance and conversion of options into ordinary fully paid shares, including numbers, issue dates, and whether the securities are cash consideration or cashless exercise. The document is a regulatory announcement about new securities being quoted, not a financial report, earnings release, or management discussion. It fits the category of Share Issue/Capital Change announcements, as it concerns new shares issued due to option exercises and their quotation on the exchange.
2023-09-05 English
Cleansing Notice 1 page 150.6KB
Regulatory Filings Classification · 95% confidence The document is a notice under section 708A(5)(e) of the Corporations Act 2001 regarding the issue of fully paid ordinary shares upon exercise of unlisted share options. It references an Appendix 2A and provides details about share issuance dates and quantities. The document is short (1469 characters) and serves as a regulatory announcement about share issuance without disclosure under part 6D.2 of the Corporations Act. It does not contain financial statements or detailed financial analysis, nor is it a report or presentation. This type of document fits the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2023-09-05 English
1H 2023 Appendix 4D and Interim Report 43 pages 3.3MB
Interim / Quarterly Report Classification · 100% confidence The document is an ASX release titled 'Results Announcement for the Half Year Ended 30 June 2023' from Telix Pharmaceuticals Limited. It includes an Appendix 4D, Directors' report, and an Interim financial report for the half-year ended 30 June 2023. The content contains detailed financial data, operational highlights, and management commentary for the half-year period, including revenue, losses, segment disclosures, and auditor's review. The document references compliance with ASX Listing Rule 4.2A, which pertains to half-year financial reporting. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year clearly identifies this as an Interim / Quarterly Report. The document is about 15,000 characters long, indicating it is the full report, not just an announcement of its publication. Therefore, the correct classification is 'IR' (Interim / Quarterly Report). H1 2023
2023-08-22 English
1H 2023 Results Release 3 pages 136.2KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'RESULTS ANNOUNCEMENT' and provides detailed financial results for the half-year ended 30 June 2023, including revenue, net loss, adjusted EBITDAR, gross margin, cash balance, and operational highlights. It discusses financial performance metrics, operational progress, regulatory approvals, and future outlook. The document also mentions an investor webcast related to these results. The length of the document (over 11,000 characters) and the presence of substantive financial data and analysis indicate this is a comprehensive interim financial report rather than a brief announcement or a certification. The content aligns with the characteristics of an Interim / Quarterly Report (IR), which covers a period shorter than a full fiscal year and includes actual financial statements and analysis. Therefore, the appropriate classification is Interim / Quarterly Report (IR). H1 2023
2023-08-22 English
1H 2023 Results Presentation 31 pages 2.4MB
Interim / Quarterly Report Classification · 95% confidence The document is a detailed presentation containing financial highlights, strategic updates, and operational commentary for the half-year period ending June 30, 2023. It includes comprehensive financial data such as revenue, earnings, adjusted EBITDA, income statement summaries, and business strategy achievements. The presence of half-year financial results and substantive financial analysis indicates this is a comprehensive interim financial report rather than a brief announcement or presentation. The document length (15,000 characters) and detailed financial content confirm it is not merely a report publication announcement or investor presentation. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2023
2023-08-22 English
Application for quotation of securities - TLX 6 pages 28.0KB
Share Issue/Capital Change Classification · 100% confidence The document is an application for quotation of securities on the ASX, detailing the issuance and conversion of options into ordinary shares. It includes specifics about the number of securities, issue dates, and the nature of the securities being quoted. This is a formal announcement related to the company's capital structure changes, specifically the issuance and quotation of new shares resulting from exercised options. It does not contain financial statements or performance data, nor is it a report or presentation. Therefore, it fits the category of Share Issue/Capital Change announcements.
2023-08-15 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.